Myeloid-derived suppressor cells as important factors and potential targets for breast cancer progression.
10.3724/zdxbyxb-2024-0353
- Author:
Nannan DU
1
,
2
;
Hua WAN
3
;
Hailing GUO
4
;
Xukuan ZHANG
3
;
Xueqing WU
5
Author Information
1. Breast Department, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200021, China. du2906689318@
2. com.
3. Breast Department, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200021, China.
4. Department of Orthopaedics and Traumatology, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200021, China.
5. Breast Department, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200021, China. snow_zi@hotmail.com.
- Publication Type:English Abstract
- Keywords:
Breast cancer;
Distant metastasis;
Immunosuppression;
Myeloid-derived suppressor cells;
Pre-metastatic niche;
Review;
Targeted therapy
- MeSH:
Humans;
Myeloid-Derived Suppressor Cells/immunology*;
Breast Neoplasms/immunology*;
Female;
Tumor Microenvironment;
Disease Progression;
Immunotherapy/methods*;
Neoplasm Metastasis;
Neoplastic Stem Cells
- From:
Journal of Zhejiang University. Medical sciences
2024;53(6):785-795
- CountryChina
- Language:Chinese
-
Abstract:
Recurrence and metastasis remain the leading cause of death in breast cancer patients due to the lack of effective treatment. A microenvironment suitable for cancer cell growth, referred to as pre-metastatic niche (PMN), is formed in distant organs before metastasis occurs. Myeloid-derived suppressor cells (MDSCs) are a heterogenous population of immature myeloid cells with immunosuppressive effects. They can expand in large numbers in breast cancer patients and participate in the formation of PMN. MDSCs can remodel the extracellular matrix of pulmonary vascular endothelial cells and recruit cancer stem cells to promote the lung metastasis of breast cancer. Furthermore, MDSCs facilitate immune evasion of breast cancer cells to impact the efficacy of immunotherapy. It is proposed that MDSCs represent a potential therapeutic target for the inhibition of recurrence and metastasis in breast cancer. Therapeutic strategies targeting MDSCs have shown promising efficacy in preclinical studies and clinical trials. This review presents a summary of the principal factors involved in the recruitment and activation of MDSCs during the formation of PMN, and outlines MDSCs functions such as immunosuppression and the current targeted therapies against MDSCs, aiming to provide new ideas for the treatment of distant metastases in breast cancer.
